Low molecular weight hyaluronic acid

Phase 3Small molecule

Low molecular weight hyaluronic acid is one of 48 small molecule programs targeting Carpal Tunnel Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carpal Tunnel SyndromeActive, not recruiting

OsteoarthritisActive, not recruiting

Carpal Tunnel SyndromePhase 3

Active, not recruiting

OsteoarthritisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Low molecular weight hyaluronic acid

IIndonesia University

Phase 3

1 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Ilaris

Novartis

Preclinical

2 4

Toradol

Roche

Preclinical

1 5

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 6

Glucophage

Boehringer Ingelheim

Preclinical

1 7

Catapres

Boehringer Ingelheim

Preclinical

1 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Paracetamol

GSK

Preclinical

4 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Not yet recruiting

Carpal Tunnel Syndrome

NCT07474714

Clinical

Trials by Indication[1]

Hyaluronic Acid1 trial

Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin Treatment

Completed·IIndonesia University·Phase 3·NCT06178367·36 enrolled

Osteoarthritis1 trial

Effectiveness of PRP, Conditioned Medium UC-MSCs Secretome and Hyaluronic Acid for the Treatment of Knee Osteoarthritis

Completed·UUniversitas Sriwijaya·Phase 1/2·NCT05579665·45 enrolled

Carpal Tunnel Syndrome1 trial

Hyaluronic Acid Injection in Idiopathic Carpal Tunnel Syndrome; is it Effective as Local Corticosteroids

Not yet recruiting·MMinia University Hospital·Phase 3·NCT07474714·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Low molecular weight hyaluronic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low molecular weight hyaluronic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low molecular weight hyaluronic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indonesia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIndonesia University

Low molecular weight hyaluronic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Hyaluronic Acid1 trial

Osteoarthritis1 trial

Carpal Tunnel Syndrome1 trial

References

Drug Info

Quick Facts

Related News